Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Katherine Gorcyca"'
Autor:
David Ansell, Franz-Werner Dippel, Şerban R. Iorga, Katherine Gorcyca, Karlheinz Theobald, Winfried März
Publikováno v:
Atherosclerosis. 268:99-107
Background and aims Elevated low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for cardiovascular (CV) events. European guidelines recommend reducing LDL-C as the primary lipid target to reduce CV risk, using lifestyle modifications
Autor:
Robert P. Giugliano, Dylan L. Steen, Robert J. Sanchez, JoAnne M. Foody, Laura Becker, Irfan Khan, Katherine Gorcyca
Publikováno v:
Clinical Cardiology. 40:155-162
Background Lowering low-density lipoprotein cholesterol with statins reduces risk of cardiovascular events. We examined patterns and predictors of filled prescriptions for lipid-lowering therapy (LLT) in subgroups of patients with atherosclerotic car
Publikováno v:
Clinical therapeutics. 40(9)
The goal of this study was to summarize patterns of lipid-lowering therapy (LLT) usage and achievement of guideline-identified lipid goals in a 2015 general practice cohort of French patients with atherosclerotic cardiovascular disease (ASCVD) and/or
Autor:
Marcello Arca, Maurizio Averna, Şerban R. Iorga, David Ansell, Aldo P. Maggioni, Georges Paizis, Katherine Gorcyca, Francesca Fanelli, Radovan Tomic, Alberico L. Catapano
Background and aims: Statin utilization and lipid goal achievement were estimated in a large sample of Italian patients at high/very-high cardiovascular (CV) risk. Methods: Patients aged â¥18 years with a valid low-density lipoprotein cholesterol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::075f105bd3e649d6e3e92e2dad6a1d4b
http://hdl.handle.net/11573/1195110
http://hdl.handle.net/11573/1195110
Autor:
Dylan L, Steen, Irfan, Khan, Laura, Becker, JoAnne M, Foody, Katherine, Gorcyca, Robert J, Sanchez, Robert P, Giugliano
Publikováno v:
Clinical cardiology. 40(3)
BACKGROUND: Lowering low‐density lipoprotein cholesterol with statins reduces risk of cardiovascular events. We examined patterns and predictors of filled prescriptions for lipid‐lowering therapy (LLT) in subgroups of patients with atheroscleroti
Autor:
Velichka Valcheva, Katherine Gorcyca, Şerban R. Iorga, Chakkarin Burudpakdee, Eli M. Roth, Joseph Elassal
Publikováno v:
Journal of the American College of Cardiology. 69:1713
Background: Alirocumab (ALI), a PCSK9-inhibitor, was approved in 7/2015, as an adjunct to diet and maximally tolerated statins for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, requiring ad
Autor:
JoAnne M. Foody, Irfan Khan, Katherine Gorcyca, Xue Song, Dylan L. Steen, Robert J. Sanchez, Christopher Hollenbeak
Publikováno v:
Journal of the American College of Cardiology. 65:A1647
Healthcare policy for reducing cardiovascular (CV) event burden should be guided by current and generalizable data. The objective was to determine the CV event risk in US patients with established atherosclerotic CV disease (ASCVD) and/or diabetes me